Guido Lancman, MD, on the Study Design of IVIG in Patients with Multiple Myeloma Receiving Daratumumab

Video

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab (Darzalex) presented at the 2020 American Society of Hematology Virtual Symposium found that hypogammaglobulinemia was nearly universal during treatment with daratumumab, suggesting a role for IVIG – especially in patients with recurrent infections.

In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, explained the design of the study and what led him and his colleagues to perform the study.

Transcription:

Sure. So, to start off, daratumumab is a CD38 monoclonal antibody. It's been shown to improve outcomes in both relapsed, refractory, and newly diagnosed myeloma. And it's overall very well tolerated. But across phase 3 studies of daratumumab there's been a consistently increased signal of infections, particularly in the respiratory tract. And since daratumumab kills not only myeloma cells, but also normal plasma cells, it can lead to decreased production of antibodies or immunoglobulins, known as hypogammaglobulinemia.

So, in our study, we actually wanted to see if replacement of immunoglobulins with IVIG, intravenous immunoglobulin, would actually decrease infection rates in patients treated with daratumumab. So, what we did is we looked at all patients at our institution who got both daratumumab and IVIG, but multiple myeloma, so it was 43 patients. And what we did was we divided their time periods into times they were getting IVIG, which was from their date of IVIG administration, until 1 month after, that's approximately how long the effect lasts for, and then the time periods there were off IVIG. And so, we compared the infection rates during those 2 time periods.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content